文献速递特殊人群用药药物不良反应与药物警戒

2型糖尿病对妊娠高血压患者硝苯地平药代动力学及胎盘转运的影响

Effect of type 2 diabetes mellitus on the pharmacokinetics and transplacental transfer of nifedipine in hypertensive pregnant women.
PubMed 文献 · Br J Clin Pharmacol · 2017-01-29

在12例妊娠高血压对照孕妇与10例合并2型糖尿病的妊娠高血压孕妇中,于孕34周采集硝苯地平缓释片(20 mg,每12小时)给药后0–12 h系列血样,分娩时采集母血、胎儿血及羊水。结果显示,在糖尿病控制良好的高血压孕妇中,2型糖尿病对硝苯地平的药代动力学及胎盘转运均无影响。

要点

  • 糖尿病控制良好时,硝苯地平在妊娠高血压孕妇中的药代动力学未见明显改变。
  • 脐静脉、绒毛间隙及羊水与母体静脉的浓度比在两组间相近。
  • 临床用药仍应关注个体差异并监测血压,但无需因合并2型糖尿病而常规调整剂量。

核心结论

  • 在糖尿病控制良好的妊娠高血压孕妇中,2型糖尿病未影响硝苯地平的药代动力学或胎盘转运。

研究设计与样本

  • 研究纳入12例妊娠高血压孕妇(对照组)和10例合并2型糖尿病的妊娠高血压孕妇,均服用硝苯地平缓释片20 mg、每12小时一次。
  • 于孕34周给药后0–12 h连续采血,分娩时采集母体血、胎儿血及羊水,测定硝苯地平在各隔室的分布。

主要发现

  • 对照组硝苯地平药代动力学参数中位值为:Cmax 26.41 ng/ml、tmax 1.79 h、AUC0-12 235.99 ng·h/ml、t½ 4.34 h、Vd/F 560.96 l、ClT/F 84.77 l/h。
  • 2型糖尿病组对应参数为:Cmax 23.52 ng/ml、tmax 1.48 h、AUC0-12 202.23 ng·h/ml、t½ 5.00 h、Vd/F 609.40 l、ClT/F 98.94 l/h。
  • 脐静脉/母体静脉浓度比在对照组和2型糖尿病组分别为0.53和0.44,绒毛间隙/母体静脉浓度比分别为0.78和0.87,羊水/母体血浆浓度比两组均为0.05。
  • 脐动脉/脐静脉浓度比在对照组为0.82,2型糖尿病组为0.88。

临床怎么用

  • 对于糖尿病控制良好的妊娠高血压孕妇,硝苯地平可按常规方案使用,无需因合并2型糖尿病而常规调整剂量。
  • 用药期间仍应结合血压监测与个体情况评估疗效和安全性。

局限性

  • 研究样本量较小,对照组12例、2型糖尿病组10例。
  • 研究对象为糖尿病控制良好的妊娠高血压孕妇,结论不宜外推至血糖控制不佳者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Diabetes mellitus can inhibit cytochrome P450 3A4, an enzyme responsible for the metabolism of nifedipine, used for the treatment of hypertension in pregnant women. We aimed to assess the effect of type 2 diabetes mellitus (T2DM) on the pharmacokinetics, placental transfer and distribution of nifedipine in amniotic fluid in hypertensive pregnant women. METHODS: The study was conducted in 12 hypertensive pregnant women [control group (CG)] and 10 hypertensive pregnant women with T2DM taking slow-release nifedipine (20 mg, 12/12 h). On the 34th week of gestation, serial blood samples were collected (0-12 h) after administration of the medication. At delivery, samples of maternal and fetal blood and amniotic fluid were collected for determination of nifedipine distribution in these compartments. RESULTS: The median pharmacokinetic parameters of CG were: peak plasma concentration (Cmax ) 26.41 ng ml-1 , time to reach Cmax (tmax ) 1.79 h, area under the plasma concentration vs. time curve from 0-12 h (AUC0-12 ) 235.99 ng.h ml-1 , half-life (t½) 4.34 h, volume of distribution divided by bioavailability (Vd/F) 560.96 l, and ClT /F 84.77 l h-1 . The parameters for T2DM group were: Cmax 23.52 ng ml-1 , tmax 1.48 h, AUC0-12 202.23 ng.h ml-1 , t½ 5.00 h, Vd/F 609.40 l, and apparent total clearance (ClT /F) 98.94 l h-1 . The ratios of plasma concentrations of nifedipine in the umbilical vein, intervillous space and amniotic fluid to those in the maternal vein for CG and T2DM were 0.53 and 0.44, 0.78 and 0.87, respectively, with an amniotic fluid/maternal plasma ratio of 0.05 for both groups. The ratios of plasma concentrations in the umbilical artery to those in the umbilical vein were 0.82 for CG and 0.88 for T2DM. CONCLUSIONS: There was no influence of T2DM on the pharmacokinetics or placental transfer of nifedipine in hypertensive women with controlled diabetes.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Filgueira GCO, Filgueira OAS, Carvalho DM, et al. Effect of type 2 diabetes mellitus on the pharmacokinetics and transplacental transfer of nifedipine in hypertensive pregnant women. Br J Clin Pharmacol. 2017. PMID: 28042936. doi:10.1111/bcp.13226

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。